Please login to the form below

Not currently logged in
Email:
Password:

Stuart Collinson joins Silence Therapeutics

He replaces Simon Sturge as non-executive director

Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

The move follows Simon Sturge's resignation as non-executive director of the biotechnology company as he seeks to focus on his other business commitments.

Dr Collinson has held senior management roles in public and private life science companies across Europe and the US, including at GlaxoWellcome, now GlaxoSmithKline, Baxter International and Cabrellis Pharmaceuticals, now part of Celgene.

He is a partner of US-based VC firm Forward Ventures and currently also serves as chairman and chief executive officer of Tioga Pharmaceuticals and director for both Arcturus Therapeutics and Essentialis.

Chief executive officer of Silence Therapeutics Ali Mortazavi said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

21st January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics